Avalon GloboCare and its Subsidiary Genexosome Technologies Announce Discovery and Development of World's First Saliva-Based Exosomal Biomarker "miR-185" as Dual Diagnostic and Therapeutic Target for Oral Cancer

Stock Information for Avalon GloboCare Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avalon GloboCare Corp.

Avalon GloboCare Announces Breakthrough in Identifying Human Angiogenic Exosomes/Extracellular Vesicles (EV) Derived from Endothelial Cells
Avalon GloboCare CEO David Jin, M.D., Ph.D. to Co-Chair the "Status of Cellular Therapy in the Asia Pacific Rim" Session at the Annual Meetings of the Transplantation and Cellular Therapy (TCT) -- ASBMT and CIBMTR Tandem Meeting 2019
OTC Markets Group Announces Quarterly Index Performance and Rebalancing
Avalon GloboCare CEO David Jin, M.D., Ph.D. to Chair and Speak at the Plenary Session of the 14th Annual World Stem Cell Summit
Avalon GloboCare Establishes Joint Venture with Arbele Limited to Co-develop Next-Generation Multi-Targeted CAR-T Cellular Immunotherapy
Avalon GloboCare to Ring the Nasdaq Stock Market Closing Bell on January 7, 2019 at 4:00 PM Eastern
Avalon GloboCare Provides Third Quarter 2018 Business Update; Reports 30% Increase in Revenues
Avalon GloboCare Announces Listing on NASDAQ Capital Market

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.